In vitro studies revealed that Dex could inhibit lung myofibroblast differentiation induced by TGF-β, which suggests that Dex may represent a potential therapeutic strategy for IPF. This evidence concerns the gene TGFB1 and idiopathic pulmonary fibrosis.